Sample AYR Quiz – Wizlink Consulting Pte Ltd

Quiz for AYR webinar

A 42-year-old female patient is recently diagnosed with diffuse cutaneous systemic sclerosis (anti-Scl-70 positive). She does not have any respiratory symptoms. The lung function test shows no sign of restriction (FVC 91%; FEV1 83%; FEV1%/FVC 91%; TLC 99%). Which further investigation would you perform?*
- None. Repeat clinical evaluation and lung function test in 3-6 months
- Chest ultrasound
- Chest radiograph
- Chest CT
Your Answer is Incorrect
Answer with Detailed explanation

Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is diagnosed in about 50% of patients diagnosed with SSc and is associated with a high mortality rate. As a substantial number of patients with SSc-ILD are asymptomatic, screening for SSc-ILD is of paramount importance. As the sensitivity and diagnostic accuracy of chest radiographs in SSc-ILD are very low, they are not indicated for ILD screening.

Lung function test is an important tool in the initial assessment and follow-up of patients with SSc-ILD. However, as the lung function test’s false-negative rate is substantial, it cannot rule out SSc-ILD. Consequently, a current evidence-based European consensus statement suggests performing a screening HRCT in all patients with SSc-ILD at baseline.

Reference:
- Hoffmann-Vold AM, et al. Arthritis Rheumatol. 2015;67(8):2205-12.
- Sulimann YA et al. Arthritis Rheumatol. 2015;67(12):3256-61.
- Hoffmann-Vold AM et al. Lancet Rheumatology. 2020;2:e71-e83.
By Prof Helmut Prosch, Associate Professor of Radiology, University of Vienna, Austria
Your Answer is Correct
Answer with Detailed explanation

Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is diagnosed in about 50% of patients diagnosed with SSc and is associated with a high mortality rate. As a substantial number of patients with SSc-ILD are asymptomatic, screening for SSc-ILD is of paramount importance. As the sensitivity and diagnostic accuracy of chest radiographs in SSc-ILD are very low, they are not indicated for ILD screening.

Lung function test is an important tool in the initial assessment and follow-up of patients with SSc-ILD. However, as the lung function test’s false-negative rate is substantial, it cannot rule out SSc-ILD. Consequently, a current evidence-based European consensus statement suggests performing a screening HRCT in all patients with SSc-ILD at baseline.
Reference:
- Hoffmann-Vold AM, et al. Arthritis Rheumatol. 2015;67(8):2205-12.
- Sulimann YA et al. Arthritis Rheumatol. 2015;67(12):3256-61.
- Hoffmann-Vold AM et al. Lancet Rheumatology. 2020;2:e71-e83.
By Prof Helmut Prosch, Associate Professor of Radiology, University of Vienna, Austria

Quiz for AYR webinar

Reference: Hoffmann-Vold AM, et al. Arthritis Rheumatol. 2015;67(8):2205-12. Sulimann YA et al. Arthritis Rheumatol. 2015;67(12):3256-61. Hoffmann-Vold AM et al. Lancet Rheumatology. 2020;2:e71-e83. By Prof Helmut Prosch, Associate Professor of Radiology, University of Vienna, Austria

Reference:

Hoffmann-Vold AM, et al. Arthritis Rheumatol. 2015;67(8):2205-12.

Sulimann YA et al. Arthritis Rheumatol. 2015;67(12):3256-61.

Hoffmann-Vold AM et al. Lancet Rheumatology. 2020;2:e71-e83.

By Prof Helmut Prosch, Associate Professor of Radiology, University of Vienna, Austria